Chief Economist, Heteronomics

Phil Rush

Philip Rush is the Founder and Chief Economist of Heteronomics. Until launching in November 2016, he was Nomura's Senior European Economist and was the Chief UK Economist there since 2010. Before that, he was UK Economist at Barclays Wealth, where he also developed strategic asset allocation models for their market return portfolios. Philip started his career at Lehman Brothers covering the UK, Scandinavian and Swiss economies. A book on his fundamental framework was published in January 2018 as "Real Market Economics".

Chief Economist

Prosperity/ Economy/ Probity/ Equity/ Property

Heteronomics

Heteronomics represents a different kind of economics. We believe analysis should delve into the details of what is really going on, rather than using overly simplistic assumptions to quick-sell stories. Independence from myopic institutional pressures allows us to focus on the realities underlying your asset allocation decisions, without the conflicts of the old market structures. Heteronomics targets the themes driving UK asset prices, offering the benefits of depth, independence and ultimately price.

UK-centric macro research

Macroeconomics

<ul>
<li><em>The US and EU are catching up with the UK’s successful vaccination programme, with all set to offer doses across their adult populations this summer. Unfortunately, global infection rates are near record highs as most of the world still can’t access vaccines.</em></li>
<li><em>Vaccine-evasive strains already circulate and are motivating boosters in Q4 ahead of a likely rise in infections. A reduced mortality risk is not guaranteed, so risk-minimising politicians may buy time for the booster campaign with renewed restrictions.</em></li>
</ul>


The US and EU are catching up with the UK’s successful vaccination programme, with all set to offer doses across their adult populations this summer. Unfortunately, global infection rates are near record highs as most of the world still can’t access vaccines.
Vaccine-evasive strains already circulate and are motivating boosters in Q4 ahead of a likely rise in infections. A reduced mortality risk is not guaranteed, so risk-minimising politicians may buy time for the booster campaign with renewed restrictions.


Covid: Policy Optimising Risk over Returns